Case Discussion: High Disease Burden and TP53 Co‑Mutation

This episode focuses on a higher‑risk clinical scenario: a patient with L858R EGFR‑mutant metastatic NSCLC, TP53 co‑mutation, bulky systemic disease, and brain metastases with edema. The speakers characterize this as aggressive biology that clearly warrants upfront combination therapy rather than monotherapy. They discuss how TP53 co‑mutation is associated with poorer prognosis and review emerging Mariposa subgroup data supporting improved outcomes with amivantamab plus a TKI in this population. Management of symptomatic brain metastases is addressed, emphasizing the need for close collaboration with radiation oncology and neuro‑oncology to balance early systemic therapy against timely local control. The conversation also highlights how overall disease burden, CNS symptoms, and patient motivation for aggressive disease control guide regimen selection. This case illustrates why combination therapy is increasingly viewed as the default for fit, higher‑risk patients in the EGFR‑mutant metastatic setting.